TBPH Q2 2021 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-14.0% YoY

Gross Profit

-$38M-295.6% margin

Operating Income

-$64M-496.4% margin

Net Income

-$52M-405.8% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-9.4%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$429M

Total Liabilities

$730M

Stockholders' Equity

-$300M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$15M	-14.0%
Gross Profit	-$38M	$15M	-354.4%
Operating Income	-$64M	-$72M	+11.2%
Net Income	-$52M	-$63M	+16.7%

Revenue Segments

Nebulized T D4208

$160M73%

Future Potential Combination Products

$45M21%

Co Promote Agreement

$11M5%

Collaborative Arrangement Revenue

$2M1%